Name: Pinealon
Brand: PeptidesDirect
SKU: PD-PINEALON-10MG
Price: 43.99 EUR
Availability: OutOfStock

Question 1

What is Pinealon?

Accepted Answer

Pinealon is a synthetic tripeptide of glutamic acid, aspartic acid and arginine (Glu-Asp-Arg, abbreviated EDR). It belongs to the Khavinson short-peptide bioregulator series, developed at the St. Petersburg Institute of Bioregulation and Gerontology, and is studied in the context of brain and neuronal tissue, with the proposed mechanism summarised in a 2020 review from the same programme (PMID 33396470). We supply it as a lyophilized powder for laboratory research only: it is not an approved medicine and is not intended for human or animal use.

Question 2

What does EDR stand for?

Accepted Answer

EDR is the single-letter amino-acid code for the peptide's sequence: E for glutamic acid, D for aspartic acid and R for arginine, written out as H-Glu-Asp-Arg-OH. The free peptide has the molecular formula C15H26N6O8, an average molecular weight of 418.4 g/mol and a monoisotopic mass of 418.18 Da (PubChem CID 10273502, CAS 175175-23-2). Material supplied as an acetate salt weighs more per mole than the free peptide, so molar calculations should start from the certificate of analysis for the batch in hand rather than from the vial label alone. The same single-letter convention runs across the Khavinson programme, for example AEDG for Epitalon's four-residue sequence (Ala-Glu-Asp-Gly); Thymalin has no equivalent single-letter code because it is a peptide complex rather than one defined sequence. In the published literature and on this page, Pinealon is frequently referred to simply as EDR rather than by its full chemical name.

Question 3

How is Pinealon related to Epitalon?

Accepted Answer

Both come from the same Khavinson bioregulator programme, but they are different peptides with a different tissue focus. Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied around the pineal gland and telomeres, while Pinealon is a tripeptide (Glu-Asp-Arg) studied in the context of brain and neuronal tissue. Both are short peptides with one defined sequence; Thymalin, the programme's thymus-focused preparation, is a different kind of product, a peptide complex without a single defined sequence, so it is not a direct structural comparison to either. Epitalon and Pinealon are commonly researched as companions rather than substitutes.

Question 4

What is the proposed mechanism?

Accepted Answer

The Khavinson programme proposes that these short peptides enter cells and regulate gene expression. What has actually been observed is narrower: fluorescently labelled Pinealon has been detected inside the cell nucleus, and the intact peptide has interacted with isolated DNA in cell-free biophysical assays (PMID 22117547, PMID 30762356). Direct binding to chromatin inside living cells and a causal effect on transcription have not been demonstrated. Pinealon is therefore framed as a candidate regulator of gene expression rather than a receptor agonist, but this is the programme's own model, set out in a 2020 review (PMID 33396470), with limited independent confirmation.

Question 5

How strong is the evidence for Pinealon?

Accepted Answer

It should be treated as preliminary. Most of the published work comes from the Khavinson group and appears largely in Russian-language journals, with limited independent replication outside that programme. The most relevant supporting papers are in-vitro work on labelled-peptide localisation and DNA binding (PMID 22117547, PMID 30762356) and a 2024 paper using aged human-derived neurons (PMID 39518916), but none of these are large studies and none involve living humans. There are no randomised human trials, and Pinealon is not an approved medicine anywhere.

Question 6

What endpoints does the laboratory research examine?

Accepted Answer

Published work focuses on neuronal cell cultures under stress, such as oxidative stress (PMID 21978084) or an amyloid-synaptotoxicity model of Alzheimer's disease (PMID 28853087), looking at cell survival, reactive oxygen species and markers of programmed cell death. Animal work within the programme, such as a prenatal rat model of hyperhomocysteinemia (PMID 22567179), examines behavioural and cognitive endpoints in the offspring rather than in a treated adult.

Question 7

What doses were used in the published Pinealon research?

Accepted Answer

The published human work with Pinealon is small, mostly Russian-language and largely from the Khavinson programme, but it does state exposures. In a two-week study in locomotive-brigade workers, participants took one capsule containing 100 micrograms of Pinealon twice a day, so 200 micrograms per day by mouth (PMID 22708445). Further human reports describe courses in 32 patients aged 41 to 83 with chronic polymorbidity and organic brain syndrome (PMID 26390612) and a 110-patient comparison of geroprotective methods (PMID 28539017), neither of which states a dose in its abstract. The preclinical work is separate again: cell cultures are exposed to defined concentrations in the medium and animals receive per-animal amounts, for example in the prenatal rat model (PMID 22567179), and neither figure translates into a human dose. Two things matter when reading those numbers. The published human exposures are oral capsules in the microgram range rather than injections, whereas this listing offers 10 mg and 20 mg lyophilized vials for laboratory use. And the milligram-per-day schedules that circulate on vendor and forum pages sit far above the only published human daily amount, are not derived from controlled research, and are not reproduced here. None of this is a protocol, and this material is supplied for laboratory research only.

Question 8

What side effects are reported?

Accepted Answer

There is no controlled human safety database for Pinealon, so no reliable side-effect profile exists. Absence of reported effects in the animal and cell-culture literature is not evidence of human safety: it reflects the absence of proper trials, not a clean safety record. This is one of the clearest limitations of the whole Khavinson short-peptide category, and it is one more reason this material is supplied for laboratory research only, not for use in or on a person or animal.

Question 9

How is Pinealon reconstituted?

Accepted Answer

Published protocols use bacteriostatic or sterile water. Add the water slowly down the inner wall of the vial and swirl gently instead of shaking, to avoid excess agitation of the peptide. The published in-vitro work reconstitutes to whatever concentration a given culture experiment required, not to one fixed volume, so there is no single reconstitution ratio specified across the literature. Reconstitution technique, water quality and the resulting solution are entirely the researcher's own responsibility.

Question 10

How should Pinealon be stored?

Accepted Answer

Sealed vials: 2 to 8 °C, protected from light. After reconstitution: 2 to 8 °C, used within about four weeks. The lyophilized powder is markedly more stable than peptide already in solution, which is why we ship it freeze-dried rather than pre-mixed. Repeated freeze-thaw cycles and storage at room temperature are not recommended for any short peptide of this kind, Pinealon included, and can shorten how long a reconstituted solution stays usable.

Question 11

What purity is the material?

Accepted Answer

The 20 mg vial is covered by a batch-specific third-party Janoshik certificate for the current Yellow Cap batch: 99.39% purity by HPLC and a measured content of 25.38 mg per vial, published on this page with a report key that can be verified directly with the lab. For the 10 mg vial, our >=99% by HPLC figure remains a purchasing specification agreed with our supplier, with identity confirmed by mass spectrometry: no 10 mg batch has arrived yet, so none has been tested against that specification. Once a 10 mg batch is in stock, its own certificate of analysis will be published on this page and on our lab-reports page before it goes on sale.

Question 12

Do you provide a CoA?

Accepted Answer

For the 20 mg vial, yes: the current Yellow Cap batch carries a batch-specific third-party certificate of analysis from Janoshik, commissioned through the supply chain rather than by us, covering identity, purity and measured content. It is published on this page with a report number that can be verified directly with the lab. The 10 mg vial does not have a certificate yet: no batch has arrived, and our standard is that its batch-specific report will be published on this page before that batch goes on sale.

Question 13

Is Pinealon approved as a medicine?

Accepted Answer

No. Pinealon has no marketing authorisation from the EMA, the FDA or any other medicines regulator anywhere, and it is not a recognised pharmaceutical ingredient under any brand or generic name. We are not aware of any clinical development programme or manufacturer seeking approval for it. It is supplied strictly as a research material for laboratory use, not for human or animal consumption.

Question 14

Why does the page say "Back soon"?

Accepted Answer

The product is listed but not currently in stock: no batch has arrived yet. Leave your email on this page and we will notify you as soon as it is back in stock, the same process we use for every other temporarily unavailable product on this site. The batch documentation, including its third-party certificate of analysis once a batch exists to test, will be published on this page before that batch goes on sale.

Question 15

Where do you ship Pinealon?

Accepted Answer

We ship EU-wide from inside the EU, so EU customers face no US customs step. Shipping is tracked via DHL. Non-EU destinations such as Norway and the United Kingdom cross a customs border and travel at the buyer's own import risk, which can add time and, depending on the destination, local import charges. A small number of destinations are excluded for regulatory reasons, which is shown at checkout.

Question 16

What form does Pinealon arrive in?

Accepted Answer

A lyophilized (freeze-dried) powder in a sealed vial, the standard form used across the published research on Pinealon and across the wider Khavinson short-peptide series. It needs reconstitution with a suitable solvent, such as bacteriostatic or sterile water, before any laboratory use: the vial is not ready to use as supplied, and the dry powder should not be substituted for a pre-dissolved solution in a protocol that specifies one.

Question 17

Who is Khavinson and what is this research programme?

Accepted Answer

Vladimir Khavinson is a Russian gerontologist who has led a decades-long research programme, based at the St. Petersburg Institute of Bioregulation and Gerontology, into short peptides isolated from or modelled on animal tissue extracts, referred to within the programme as bioregulators or cytogens. Pinealon, Epitalon and Thymalin all come out of this programme, each associated with a different tissue. The programme has produced a large body of laboratory and animal literature over several decades, almost entirely from the same research group, which is the central caveat that runs through this whole page.

Question 18

Why is so much of the Pinealon literature in Russian?

Accepted Answer

Much of the foundational work on Pinealon and related short peptides was published in Russian-language journals, particularly Uspekhi Gerontologii (Advances in Gerontology), including animal studies indexed under PMID 28509493, PMID 28976148, PMID 21809624 and PMID 25051764. That reflects where the Khavinson programme is based, not a hidden or informal source: the papers are peer-reviewed and indexed in PubMed. The practical effect is that these papers are read by fewer international reviewers than an equivalent English-language journal would attract, and independent replication outside Russian-language gerontology journals remains limited. We treat this as a reason for caution, not as a reason to dismiss the work outright.

Question 19

What is a cytogen?

Accepted Answer

Cytogen is the term the Khavinson programme uses for a short peptide bioregulator proposed to act on a specific cell type or tissue, on the idea that a short sequence can carry tissue-selective regulatory information into a cell (PMID 33396470). Pinealon, described within the programme as the cytogen for neuronal tissue, and Epitalon, described as the cytogen for the pineal gland, are examples. It is the programme's own classification, not an established pharmacological category recognised outside that literature.

Question 20

Is there any human trial evidence for Pinealon?

Accepted Answer

No. Every study cited on this page is either an animal model or an in-vitro cell-culture experiment; there is no published, controlled human trial of Pinealon at any dose. That includes the prenatal rat study (PMID 22567179), the induced-neuron culture work (PMID 39518916) and the hippocampal-neuron Alzheimer's model (PMID 28853087). Anyone presenting a human regimen for Pinealon is not citing research, because none exists.

Question 21

Does entering the cell nucleus mean Pinealon regulates a gene?

Accepted Answer

Not on its own. Fluorescently labelled Pinealon has been observed inside the cell nucleus, and the intact peptide has interacted with isolated DNA in cell-free biophysical assays (PMID 22117547, PMID 30762356) and, separately, with histone proteins in vitro (PMID 23581987). That is different from showing that the peptide binds a specific gene's chromatin inside a living cell and changes how much of that gene's product is made. A 2020 review from the same programme sets out gene-expression regulation as the proposed mechanism (PMID 33396470), but this remains a model built from indirect evidence, not a demonstrated cause-and-effect pathway confirmed by independent groups.

Question 22

How does Pinealon compare with Epitalon in the research?

Accepted Answer

They are studied with a similar conceptual framework, a short peptide with a proposed gene-regulatory role in a specific tissue, but they are different molecules with a different tissue focus and separate, non-overlapping sets of published studies. Epitalon's literature centres on the pineal gland, telomerase activity and circadian markers. Pinealon's centres on neuronal cell cultures, oxidative stress and cognitive endpoints in animal models such as the prenatal rat study (PMID 22567179). Neither has a controlled human trial, and both come from the same research group, so the same evidence caveats apply to each independently, not just when they are combined.

Question 23

What does the most recent published work on Pinealon show?

Accepted Answer

The most recent study cited on this page is a 2024 paper using induced cortical neurons made from the skin cells of elderly human donors (PMID 39518916). Researchers added Pinealon's EDR sequence to the culture medium daily for 10 days at 10 micrograms per mL and reported effects on markers of neuronal ageing in these cells. It is still an in-vitro study using cells derived from a small number of donors, not a clinical study in living people, and it has not yet been independently replicated.

Question 24

Given how thin the evidence is, why do you list Pinealon at all?

Accepted Answer

Because there is a genuine, published, PubMed-indexed research literature behind the peptide, even though it is preliminary, largely single-group and Russian-language-heavy, including work as recent as 2024 (PMID 39518916). We sell to researchers who want to study exactly that kind of early-stage bioregulator, and we would rather describe the evidence accurately, limits included, than either refuse to list a real research compound or oversell it as more established than it is. Understating a preliminary evidence base is the safer error, and it is the one we choose.

Question 25

Does unrefrigerated shipping affect the quality of this product?

Accepted Answer

No. This product ships as a lyophilized (freeze-dried) powder in a sealed vial. Freeze-drying removes the water that drives peptide degradation, so the dry powder remains stable at room temperature for extended periods, longer than any normal parcel transit. Ambient shipping is standard practice across the peptide industry, and a peer-reviewed study reported months of room-temperature stability for a lyophilized therapeutic peptide (teriparatide, PMID 26620825). For comparison, FDA labeling allows an Ozempic (semaglutide) pen, after first use, to be kept out of the fridge for 56 days at 15 to 30°C, and a Mounjaro (tirzepatide) pen for up to 21 days at up to 30°C, even though these are ready-mixed solutions rather than sealed dry powder. Store the sealed vial in the fridge or freezer for long-term storage, and always refrigerate after reconstitution.

Question 26

What dose, route and duration were used when the EDR tripeptide was given to 5xFAD mice?

Accepted Answer

The cited 5xFAD mouse study administered EDR and KED intraperitoneally at 400 micrograms per kilogram once daily for two months before the electrophysiological or morphological experiments (PMID 34071923, methods in the full text PMC8227791). The endpoints were laboratory measures rather than clinical ones, and the reported result is narrower than the dose alone suggests: the abstract attributes the trend towards increased neuroplasticity to daily KED administration in 5xFAD mice from 2 to 4 months of age, while both peptides prevented dendritic spine loss in 5xFAD-M mice. The paper carries a 2025 correction because Figures 5 and 8 had been published as the same image with different descriptions, the authors stating that the scientific conclusions are unaffected (PMID 39861198). Cell culture work reports concentrations instead of body weight doses: EDR at 200 ng/ml increased the number of mushroom spines by 71% in primary culture of mouse hippocampal neurons under amyloid synaptotoxicity (PMID 28853087). None of these figures translates into a human schedule.

Question 27

Was the published human research on Pinealon done with injections or with oral capsules?

Accepted Answer

The human reports that state a route describe oral Pinealon, while the abstract of PMID 26390612 does not specify a route and the cited ClinicalTrials.gov search returned zero records (query.term=pinealon, totalCount 0). A field study in workers of locomotive brigades states the regimen explicitly: the preparation was used during two weeks, one capsule containing 100 micrograms of Pinealon twice a day (PMID 22708445). A 2020 review summarises the clinical claims the same way: it reports oral administration of Pinealon in addition to standard therapy in 72 patients with traumatic brain injury consequences and cerebrasthenia, and concludes that the EDR peptide possessed neuroprotective properties when administered orally (PMID 33396470, a review). The third human paper covers 32 people aged 41 to 83 with polymorbidity and organic brain syndrome in remission and names the preparations vesugen and pinealon without giving a route in its abstract (PMID 26390612). None of the cited human reports describes subcutaneous administration.

Pinealon

What is Pinealon

How it works

Often studied alongside

Documentation

Storage and stability

Reviews

Frequently Asked Questions

Frequently bought together

Bacteriostatic Water

Lab Measuring Syringe + Prep Wipes Set (1 mL 31G)

Graduated Measuring Syringe 1 mL 31G x 6 mm

Alcohol Prep Pads 30 x 65 mm

Peptide Storage Box (10 Compartments)

Peptide Vial Case 30 Slots